Visit LathamDrive – A new site with resources to help emerging companies grow.

Jim Morrone

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA
 
 

Jim Morrone is a partner in the Silicon Valley office of Latham & Watkins. Mr. Marrone primarily represents technology and life sciences emerging growth companies (public and private) and their funding sources, including venture capital and private equity firms and investment banks. Prior to joining Latham & Watkins, Mr. Morrone was a Principal and Senior Counsel at Weston Presidio, a venture capital and private equity firm focused primarily on retail, consumer, and industrial investments.

Mr. Morrone’s practice includes assistance with:

  • Early-stage formation and strategy
  • Venture capital financings
  • 144A and public offerings 
  • Mergers and acquisitions
  • Corporate governance
  • Federal and state securities law compliance

Mr. Morrone served on the editing team for the production of Latham's Emerging Companies Book of Jargon.

Mr. Morrone's representative experience includes:

Venture Financings

Represented numerous emerging companies in venture capital financings and other minority investments, including seed financings, early, middle and late stage preferred stock financings, bridge financings, pay-to-play, cram downs, convertible debt, convertible equity, and LLC membership unit issuances. Select company transactions include:

AdRoll, Chess.com, Fantex, Hearsay Social, Heliotrope Technologies, HotelTonight, Intermolecular, Marine Layer, One Concern, Pearl Automation, Soraa, Stion, Wikia, and Wise Sons.

Represented numerous venture capital funds and strategic investors in similar financings. Investor representations include:

Abingworth, Accel, Benchmark, Bessemer, Buran Capital, DAG Ventures, Formation 8, Foundation Capital, GI Partners, H.I.G. Capital, Intuit, Institutional Ventures Partners (IVP), Khosla, LDVP, Lightspeed, Mayfield, Monsanto Growth Ventures, Riverwood, Sberbank, Sequoia, Sierra Ventures, Servco, Trinity Capital, Temasek, USVP, and Weston Presidio.

144A and Public Offerings

Represented both issuers and underwriters in public and private offerings of debt and equity:

  • Aviron in underwritten public offering of debt and equity
  • BofA Merrill Lynch in connection with convertible note financing for Salesforce.com
  • BofA Merrill Lynch and Morgan Stanley in connection with convertible note financing for Salesforce.com
  • Citigroup and Merrill Lynch in connection with public offering of equity of Asyst Technologies
  • Citigroup in connection with the IPO of Anacor Pharmaceuticals, and Leerink in connection with the follow-on public offering of equity of Anacor Pharmaceuticals
  • Citigroup in connection with the IPO of Tesaro, and numerous follow-on public offerings of debt and equity of Tesaro
  • Conceptus in its IPO and subsequent PIPE transaction
  • CV Therapeutics in private placement of subordinated convertible notes, numerous registered direct offerings to individual investors and in its equity line of credit arrangement with Acqua Wellington
  • Fantex in multiple IPOs of different tracking stocks 
  • Goldman, Sachs and J.P. Morgan in connection with the IPO of Global Cash Access
  • Intermolecular in its IPO
  • Jefferies in connection with the IPO of Aquinox Pharmaceuticals, and Leerink in connection with the follow-on public offering of equity of Aquinox Pharmaceuticals 
  • Lehman Brothers and Merrill Lynch in connection with the IPO of ZymoGenetics
  • Piper Jaffray in connection with the IPO of Cutera
  • Piper Jaffray and J.P. Morgan in connection with the IPO of FoxHollow
  • Sunesis Pharmaceuticals in its IPO

Mergers & Acquisitions

  • Adroll in its acquisition of Bitdeli, Userfox, and other “Acqui-hires”
  • Angiogenix (private) in its acquisition of substantially all the assets of NitrOSystems, Inc. (private)
  • Aviron (public) in its acquisition by MedImmune (public)
  • BrandVia (private) in its acquisition of substantially all the assets of iPrint.com (public) through an assignment for the benefit of creditors
  • Calix (public) in its acquisition of Occam Networks (public)
  • CellGate (private) in its acquisition of a significant portion of the assets of SLIL Biomedical Corp. (private)
  • Connectix (private) in its sale of substantially all of its assets to Microsoft (public)
  • Delivery Agent (private) in numerous acquisitions, including The Band and Clean Fun Marketing
  • HotPotato (private) in its acquisition by Facebook
  • Intermolecular (private) in its acquisition of substantially all the assets of Siorah (private)
  • Map Pharmaceuticals (public) in its acquisition by Allergan (public)
  • Mixr (private) in its acquisition by SpeedDate.com (private)
  • Redwood Systems (private) in its acquisition by CommScope (public)
  • Sensory Networks (private) in its acquisition by Intel (public)
  • Spectra Linear (private) in its acquisition by Silicon Labs
  • Stion (private) in its acquisition of substantially all the assets of CM Manufacturing (private) through an assignment for the benefit of creditors
  • Sutherland Global Services (private) in its acquisition of Apollo Health Street Ltd. (private)
  • 3i Venture Partners and VantagePoint Venture Partners in connection with the acquisition by SCP Global Technologies (private) of a foreigh division of Mattson technology (public)
  • Vantage Point Venture Partners in connection with its acquisition of the Thermal Division of ASML US, a wholly-owned subsidiary of ASML Holding N.V., a Dutch company (public)
  • Weston Presidio and Dorset Capital in connection with the leveraged recapitalization of Hanna Andersson Corporation (private)
  • Weston Presidio and Dorset Capital in connection with the leveraged acquisition of William Pitt, LLC, d/b/a Robbin Bros. (private)
  • H.I.G. Capital LLC in leveraged buyout of a retailer
  • Numerous LBO transactions relating to Weston Presidio portfolio companies

Thought Leadership

  • Term Sheet Tips For Emerging Companies Seeking Venture Money
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.